CPhI Online

- Market News

Samsung Biologics invests in expanding aseptic filling capacity at Incheon site

21 Jul 2020

Through this expansion, the CDMO will increase the total lyophilization capacity by 246% of the current capacity.

Samsung Biologics has announced plans to expand its drug product capability at its Incheon (South Korea) facility in line with increasing market demand and to ensure flexible production capabilities for new and existing clients.

In response to the forecasted increase in demand for aseptic filling, the contract manufacturing and development organization (CDMO) is making a strategic investment on its global capacity by building a flexible filling line and two additional lyophilizer units with 41.2 m2 chambers.

The flexible filling line is expected to commence good manufacturing practice operations in the second half of 2021, and the expanded lyophilization line will become operational in the first half of 2022.

Through this expansion, Samsung Biologics will add small-scale cartridge and syringe filling to its drug product offerings, and increase the total lyophilization capacity by 246% of the current capacity. The company expects to demonstrate its ongoing commitment to reliability and quality-oriented services for its clients and strengthen existing partnerships in addition to procuring new orders.

Dr Tae Han Kim, CEO of Samsung Biologics. said that through this investment, the company hopes to "offer more flexibility" and demonstrate its "extensive manufacturing capabilities with the largest production capacity in the industry".